FORXIGA® (dapagliflozin)

FORXIGA® (dapagliflozin) is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1

Prescribing FORXIGA® (dapagliflozin) before a DPP-4 inhibitor could set change in motion for your patients

When diabetes control is needed, what more could you do for your patients?

FORXIGA®(dapagliflozin) vs saxagliptin

In a post-hoc analysis, when added to metformin, FORXIGA® (dapagliflozin) showed greater HbA1c reduction than saxagliptin, a DPP-4i 30

Post-hoc analysis comparing HbA1C reduction with FORXIGA® + metformin with saxagliptin + metformin
Post-hoc analysis comparing HbA1C reduction with FORXIGA® + metformin with saxagliptin + metformin

Adapted from Rosenstock J et al. 2016

*Number of randomised patients with non-missing baseline values at Week 24 values last observation carried forward.30
A post-hoc analysis was conducted to investigate the efficacy of dapagliflozin + metformin vs saxagliptin + metformin. This analysis was not pre-specified in the statistical analysis plan of Rosenstock J et al 2015.
DPP-4i, dipeptidyl peptidase-4 inhibitor; CI, confidence interval.

In the absence of direct comparisons between dapagliflozin and saxagliptin a post-hoc analysis was conducted to compare the efficacy and safety of dapagliflozin versus saxagliptin in patients with T2DM.30 This post-hoc analysis from a 24-week clinical trial3, in poorly controlled (HbA1c ≥8.0% and ≤12.0%), metformin-treated (≥1500 mg/day), patients with T2DM, compared dapagliflozin 10 mg (n = 179) with saxagliptin 5 mg (n = 176) as add on therapy to metformin.30

Outcomes measured included: reanalysis of the primary endpoint (adjusted mean change from baseline in HbA1c after 24 weeks of double-blind treatment); reanalysis of the secondary endpoints: adjusted mean change from baseline at 24 weeks in fasting plasma glucose, adjusted mean change from baseline at 24 weeks in 2-h postprandial glucose, and the adjusted mean change from baseline in bodyweight; composite efficacy endpoint analysis of dapagliflozin versus saxagliptin added to metformin; and overall adverse events and adverse events of special interest.  

In a post-hoc analysis, when added to metformin, the secondary benefit of weight loss was seen with FORXIGA® (dapagliflozin), but not with saxagliptin 30

Post-hoc analysis comparing weight loss with FORXIGA®+ metformin with saxagliptin + metformin
Post-hoc analysis comparing weight loss with FORXIGA®+ metformin with saxagliptin + metformin

Adapted from Rosenstock J et al. 2016

FORXIGA® (dapagliflozin) is not indicated for weight loss. Weight change was a secondary endpoint in clinical trials.1

*Number of randomised patients with non-missing baseline values at Week 24 values last observation carried forward. 3

 Saxagliptin is not indicated for weight loss.31
DPP-4i, dipeptidyl peptidase-4 inhibitor; CI, confidence interval.

In the absence of direct comparisons between dapagliflozin and saxagliptinpost-hoc analysis was conducted to compare the efficacy and safety of dapagliflozin versus saxagliptin in patients with T2DM.30 This post-hoc analysis from a 24-week clinical trial3, in poorly controlled (HbA1c ≥8.0% and ≤12.0%), metformin-treated (≥1500 mg/day), patients with T2DM, compared dapagliflozin 10 mg (n = 179) with saxagliptin 5 mg (n = 176) as add on therapy to metformin.30

Outcomes measured included: reanalysis of the primary endpoint (adjusted mean change from baseline in HbA1c after 24 weeks of double-blind treatment); reanalysis of the secondary endpoints: adjusted mean change from baseline at 24 weeks in fasting plasma glucose, adjusted mean change from baseline at 24 weeks in 2-h postprandial glucose, and the adjusted mean change from baseline in bodyweight; composite efficacy endpoint analysis of dapagliflozin versus saxagliptin added to metformin; and overall adverse events and adverse events of special interest.  
 

FORXIGA® (dapagliflozin) dosing

Simple dosing for you and your patients

Simple dosing with FORXIGA®(dapagliflozin): one pill, once a day 1
 

Simple dosing with FORXIGA®
Simple dosing with FORXIGA®

 

*No dosage adjustment is necessary for patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, the dose may be increased to 10 mg.